{"prompt": "['8', '6.2: Inclusion visit and Screening phase', '29', '6.3: Study procedure', '29', '6.3.1: Part one (Repeatability)', '29', '6.3.2: Part 2 (Stability)', '29', '6.4: End of the study', '29', '6.5: Stopping rule', '30', '6.6: Report of serious adverse effect (SAE)', '30', '6.7: Study duration', '30', 'VII: Project management and Monitoring', '31', '7.1: Project management', '31', '7.2: Publication of the results', '31', '7.3: Quality assurance demands', '31', '7.4: Start-up and closing visit', '31', '7.5: Monitoring procedure', '31', '7.6: Curriculum vitae', '32', '7.7: Site file', '32', 'VIII: Data Management', '33', '8.1. Case Record Forms (CRF)', '33', '8.2. Study Database', '33', 'IX: Discontinuation', '34', '9.1: Discontinuation not related to the study question', '34', '9.2: Discontinuation related to the study question', '34', 'X: Ethical consideration', '35', '10.1: Consideration of steering committee', '35', '10.2: Approval of the project', '35', '10.3: Informed consent', '36', '10.4: Protection of personal data', '36', 'XI: Statistical model', '37', '11.1: Handling of discontinuation', '37', '11.2: Presentation of the result', '37', '11.3: Sample size', '37', 'XII: Operational matters', '38', \"12.1: Investigator's agreement\", '38', '12.2: Instructions', '38', '12.3: Amendments to the protocol', '38', '12.4: Protocol deviations', '38', '12.5: Compliance monitoring', '38', '12.6: Responsibilities', '38', '12.7: Confidentiality', '38', '12.8: Investigator and Sponsor withdrawals', '39', 'XIII: References', '40', 'XIV: Amendments', '42', 'XV: Appendix', '45', \"15.1: Set of CRF's\", '45', '15.1.1: CRF I; Inclusion and exclusion', '45', '15.1.2: CRF II; Demographic factors', '47', '15.1.3: CRF III; Medical history', '48', '15.1.4: CRF IV; Quality of life', '50', '15.1.5: CRF V; Adverse Events', '52', '15.1.6: CRF VI; Adverse Events', '53', '15.1.7: CRF VII; End of Trial', '54', '15.2: Bulbicam Certificate', '55', 'BulbiCam; Validity study:', '71 OTH/DR; AMD-I/2022:', 'Final Version 1.5 22nd March 2022']['9', '15.2.1: ISO-Certificate', '55', '15.2.2: Certificate of free Sales', '56', '15.3: CV; Primary investigator & Steering Committee', '57', '15.3.1: Bard Dalhoi CEO BulbiTech AS', '57', '15.3.2: Professor Goran Petrovski; Ophthalmology', '60', '15.3.3: Professor Stig Larsen', '61', 'BulbiCam; Validity study:', 'V1_OTH/DR; AMD-I/2022:', 'Final Version 1.5_22nd March 2022']\n\n###\n\n", "completion": "END"}